The Transferrin Receptor Protein 1 pipeline drugs market research report outlays comprehensive information on the Transferrin Receptor Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Transferrin Receptor Protein 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Oncology, Musculoskeletal Disorders, and Metabolic Disorders which include the indications Unspecified Central Nervous System Disorders, Neurodegenerative Diseases, Leukemia, Solid Tumor, Myotonic Dystrophy, Muscle Atrophy, and Pompe Disease. It also reviews key players involved in Transferrin Receptor Protein 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Transferrin Receptor Protein 1 pipeline targets constitutes close to 15 molecules. Out of which, approximately 15 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 2, 2, 8, and 3 respectively.
Transferrin Receptor Protein 1 overview
Transferrin receptor protein 1 (TFRC) is a transmembrane glycoprotein composed of two disulfide-linked monomers joined by two disulfide bonds. It is a cell surface receptor necessary for cellular iron uptake by the process of receptor-mediated endocytosis. This receptor is required for erythropoiesis and neurologic development.
For a complete picture of Transferrin Receptor Protein 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
